Curi RMB Capital LLC Raises Holdings in Repligen Co. (NASDAQ:RGEN)

Curi RMB Capital LLC increased its position in shares of Repligen Co. (NASDAQ:RGEN) by 0.6% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 113,212 shares of the biotechnology company’s stock after buying an additional 685 shares during the quarter. Curi RMB Capital LLC’s holdings in Repligen were worth $16,848,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in shares of Repligen by 0.4% in the first quarter. Vanguard Group Inc. now owns 5,100,013 shares of the biotechnology company’s stock valued at $937,994,000 after buying an additional 21,719 shares during the last quarter. Bank of New York Mellon Corp raised its stake in Repligen by 21.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company’s stock valued at $172,749,000 after acquiring an additional 237,884 shares during the last quarter. Conestoga Capital Advisors LLC lifted its holdings in shares of Repligen by 26.7% during the second quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company’s stock worth $119,363,000 after purchasing an additional 199,322 shares during the period. Thrivent Financial for Lutherans increased its stake in Repligen by 240.5% in the 2nd quarter. Thrivent Financial for Lutherans now owns 601,829 shares of the biotechnology company’s stock valued at $75,866,000 after buying an additional 425,061 shares during the period. Finally, New York State Common Retirement Fund raised its position in Repligen by 14.4% during the 3rd quarter. New York State Common Retirement Fund now owns 567,044 shares of the biotechnology company’s stock worth $84,387,000 after buying an additional 71,274 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Insider Activity

In related news, Director Anthony Hunt sold 22,191 shares of the business’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the sale, the director now directly owns 139,840 shares in the company, valued at approximately $20,328,540.80. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 1.20% of the company’s stock.

Repligen Stock Up 1.3 %

RGEN opened at $150.47 on Thursday. The firm has a market cap of $8.43 billion, a P/E ratio of -406.66, a PEG ratio of 4.27 and a beta of 0.96. The business’s fifty day simple moving average is $141.59 and its 200 day simple moving average is $144.78. Repligen Co. has a 52 week low of $113.50 and a 52 week high of $211.13. The company has a quick ratio of 5.56, a current ratio of 6.65 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last announced its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.92%. The firm had revenue of $154.87 million for the quarter, compared to analyst estimates of $153.34 million. During the same quarter last year, the business earned $0.23 earnings per share. Repligen’s revenue was up 9.7% compared to the same quarter last year. As a group, equities research analysts anticipate that Repligen Co. will post 1.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on RGEN shares. Royal Bank of Canada restated an “outperform” rating and issued a $205.00 price objective on shares of Repligen in a research report on Thursday, September 26th. JPMorgan Chase & Co. raised their price objective on shares of Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research note on Wednesday, July 31st. Benchmark restated a “hold” rating on shares of Repligen in a research report on Monday, August 5th. UBS Group dropped their target price on shares of Repligen from $205.00 to $185.00 and set a “buy” rating for the company in a report on Wednesday, July 31st. Finally, Stephens reiterated an “overweight” rating and set a $170.00 target price on shares of Repligen in a research report on Tuesday, July 30th. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, Repligen currently has an average rating of “Moderate Buy” and an average price target of $190.25.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.